These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

381 related items for PubMed ID: 14607790

  • 1. Neutralizing antibodies against IFN-beta in multiple sclerosis: antagonization of IFN-beta mediated suppression of MMPs.
    Gilli F, Bertolotto A, Sala A, Hoffmann F, Capobianco M, Malucchi S, Glass T, Kappos L, Lindberg RL, Leppert D.
    Brain; 2004 Feb; 127(Pt 2):259-68. PubMed ID: 14607790
    [Abstract] [Full Text] [Related]

  • 2. Changes in matrix metalloproteinases and their inhibitors during interferon-beta treatment in multiple sclerosis.
    Comabella M, Río J, Espejo C, Ruiz de Villa M, Al-Zayat H, Nos C, Deisenhammer F, Baranzini SE, Nonell L, López C, Julià E, Oksenberg JR, Montalban X.
    Clin Immunol; 2009 Feb; 130(2):145-50. PubMed ID: 18945642
    [Abstract] [Full Text] [Related]

  • 3. Regulation of matrix metalloproteinases and their inhibitors by interferon-beta: a longitudinal study in multiple sclerosis patients.
    Bernal F, Elias B, Hartung HP, Kieseier BC.
    Mult Scler; 2009 Jun; 15(6):721-7. PubMed ID: 19383643
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Interferon-beta bioactivity measurement in multiple sclerosis: feasibility for routine clinical practice.
    van der Voort LF, Kok A, Visser A, Oudejans CB, Caldano M, Gilli F, Bertolotto A, Polman CH, Killestein J.
    Mult Scler; 2009 Feb; 15(2):212-8. PubMed ID: 18805837
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Neutralizing antibodies, MxA expression and MMP-9/TIMP-1 ratio as markers of bioavailability of interferon-beta treatment in multiple sclerosis patients: a two-year follow-up study.
    Garcia-Montojo M, Dominguez-Mozo MI, de las Heras V, Bartolome M, Garcia-Martinez A, Arroyo R, Alvarez-Lafuente R.
    Eur J Neurol; 2010 Mar; 17(3):470-8. PubMed ID: 20050906
    [Abstract] [Full Text] [Related]

  • 9. MxA protein assay for optimal monitoring of IFN-beta bioactivity in the treatment of MS patients.
    Vallittu AM, Erälinna JP, Ilonen J, Salmi AA, Waris M.
    Acta Neurol Scand; 2008 Jul; 118(1):12-7. PubMed ID: 18081914
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Interferon-beta-1 b decreased matrix metalloproteinase-9 serum levels in primary progressive multiple sclerosis.
    Yushchenko M, Mäder M, Elitok E, Bitsch A, Dressel A, Tumani H, Bogumil T, Kitze B, Poser S, Weber F.
    J Neurol; 2003 Oct; 250(10):1224-8. PubMed ID: 14586607
    [Abstract] [Full Text] [Related]

  • 12. Predictive markers for response to interferon therapy in patients with multiple sclerosis.
    Malucchi S, Gilli F, Caldano M, Marnetto F, Valentino P, Granieri L, Sala A, Capobianco M, Bertolotto A.
    Neurology; 2008 Mar 25; 70(13 Pt 2):1119-27. PubMed ID: 18272865
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Antibodies against interferon-beta in multiple sclerosis.
    Aarskog NK, Marøy T, Myhr KM, Vedeler CA.
    J Neuroimmunol; 2009 Jul 25; 212(1-2):148-50. PubMed ID: 19467718
    [Abstract] [Full Text] [Related]

  • 15. Pharmacogenetics of MXA SNPs in interferon-beta treated multiple sclerosis patients.
    Weinstock-Guttman B, Tamaño-Blanco M, Bhasi K, Zivadinov R, Ramanathan M.
    J Neuroimmunol; 2007 Jan 25; 182(1-2):236-9. PubMed ID: 17126411
    [Abstract] [Full Text] [Related]

  • 16. Matrix metalloproteinases and their tissue inhibitors as markers of disease subtype and response to interferon-beta therapy in relapsing and secondary-progressive multiple sclerosis patients.
    Galboiz Y, Shapiro S, Lahat N, Rawashdeh H, Miller A.
    Ann Neurol; 2001 Oct 25; 50(4):443-51. PubMed ID: 11601495
    [Abstract] [Full Text] [Related]

  • 17. The clinical effect of neutralizing antibodies against interferon-beta is independent of the type of interferon-beta used for patients with relapsing-remitting multiple sclerosis.
    Koch-Henriksen N, Sorensen PS, Bendtzen K, Flachs EM.
    Mult Scler; 2009 May 25; 15(5):601-5. PubMed ID: 19299439
    [Abstract] [Full Text] [Related]

  • 18. [Significance of imbalance between matrix metalloproteinases and tissue type inhibitor of metalloproteinases in renal tubulointerstitial lesions of aging rats].
    Chen RQ, Chen XM, Cui SW, Cai GY, Shi SZ, Xie YS, Lu Y, Peng LX.
    Zhonghua Yi Xue Za Zhi; 2004 Jun 02; 84(11):937-42. PubMed ID: 15329283
    [Abstract] [Full Text] [Related]

  • 19. Matrix metalloproteinase-9 and matrix metalloproteinase-2 as biomarkers of various courses in multiple sclerosis.
    Benesová Y, Vasku A, Novotná H, Litzman J, Stourac P, Beránek M, Kadanka Z, Bednarík J.
    Mult Scler; 2009 Mar 02; 15(3):316-22. PubMed ID: 19153173
    [Abstract] [Full Text] [Related]

  • 20. Early detection of neutralizing antibodies to interferon-beta in multiple sclerosis patients: binding antibodies predict neutralizing antibody development.
    Hegen H, Millonig A, Bertolotto A, Comabella M, Giovanonni G, Guger M, Hoelzl M, Khalil M, Killestein J, Lindberg R, Malucchi S, Mehling M, Montalban X, Polman CH, Rudzki D, Schautzer F, Sellebjerg F, Sørensen PS, Deisenhammer F.
    Mult Scler; 2014 Apr 02; 20(5):577-87. PubMed ID: 24009164
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.